InvestorsHub Logo
Followers 1880
Posts 137568
Boards Moderated 5
Alias Born 01/03/2007

Re: None

Monday, 05/18/2015 8:46:18 AM

Monday, May 18, 2015 8:46:18 AM

Post# of 344
Celgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares